Biotech entity
All 3 tracked stories fall under one category: pharma. Heron Therapeutics is most often covered alongside Lantheus Holdings, which appears in 2 of these 3 stories. Source depth averages 6 original sources per story, versus 3.6 across the same-window beat baseline.
Last mentioned: Feb 26, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 3 tracked stories fall under one category: pharma. Heron Therapeutics is most often covered alongside Lantheus Holdings, which appears in 2 of these 3 stories. Source depth averages 6 original sources per story, versus 3.6 across the same-window beat baseline. At 5, the average consequence score sits below the same-window beat average of 6. Heron Therapeutics appears in 3 tracked Biotech stories published from February 25, 2026 through February 26, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 34 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Heron Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
The Q4 2025 earnings reports from leading biotech and specialty pharma firms reveal a sector-wide transition toward commercial-stage CRISPR therapies and high-growth radiopharmaceuticals. Key players like Intellia and Lantheus are setting the pace for 2026, while specialty firms focus on operational efficiency and non-opioid alternatives.
Lantheus Holdings and Heron Therapeutics both reported mixed fourth-quarter financial results, highlighting a period of transition for the mid-cap biotech sector. While both companies provided initial FY26 outlooks, market attention is shifting toward their respective commercial scaling efforts and pipeline execution.
As the Q4 2025 earnings season commences, Delcath Systems, Butterfly Network, Heron Therapeutics, and Lantheus Holdings are under intense scrutiny regarding their commercial execution and path to profitability. Investors are particularly focused on Delcath's HEPZATO KIT rollout and Lantheus's ability to maintain its dominance in the competitive radiopharmaceutical market.
Heron Therapeutics is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
